US CMS ends waiver for Wisconsin Rx drug plan

22 April 2007

The US Centers for Medicare and Medicaid Services (CMS) has turned down a request by the state of Wisconsin to extend its SeniorCare prescription drug program for low-income senior citizens. The CMS argues that the local program largely duplicates the federal Medicare Part D prescription drug plan and that it fails to provide a full means test for applicants. SeniorCare is expected to be terminated at the end of this year.

The Wisconsin program was open to residents aged 65 or over with less than 240% of the federal poverty level in annual income. The scheme does not, however, measure the assets of beneficiaries. Leslie Norwalk, the CMS' Acting-Administrator, also said that she is not convinced that SeniorCare is financially justified. She told the Washington Post: "all they have done, basically, is shift costs to the Medicaid program that should not be borne there."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight